GLAMOR-P Tablets

When Control Need Two Hands


COMPOSITION: Glimepiride IP 2 mg + Pioglitazone Hydrochloride 15 mg Tabs

  • The combination is indicated in patients with type-II diabetes when diet, exercise, and the single agents do not result in adequate glycemic control.
  • Diabetes is a strong, independent risk factor for cardiovascular disease, causing a 2- to 4-fold increase in cardiovascular mortality in patients with T2D.
  • Type 2 diabetes mellitus is characterized by insulin resistance and progressive β cell failure; therefore, β cell secretagogues are useful for achieving sufficient glycemic control.


  • Type-II Diabetes Millitus





  • Drug class: Sulfonylureas
  • Glimepiride lowers blood glucose by stimulating pancreatic β cells to release insulin.
  • Shows a significant decrease in triglycerides and an increase in high-density lipoprotein.
  • Induces PPAR gamma activity, thereby improving insulin resistance.


  • Drug class: Thiazolidinediones 

Pioglitazone HCl

  • Pioglitazone hydrochloride, a thiazolidinedione compound, is a new therapeutic agent for the treatment of type 2 diabetes that reduces insulin resistance by enhancing insulin action in skeletal muscle, liver, and adipose tissue.
  • Pioglitazone HCL is a PPAR-γ agonist that increases insulin-stimulated glucose uptake in peripheral tissues.


In a study of the long-term effect of TZD, the combination was associated with significantly reduced plasma lipoprotein (a) levels, a known risk factor for cardiovascular disease, compared with the rosiglitazone combination